PD-L1 expression predicts efficacy in the phase II SPiReL trial with MVP-S, pembrolizumab, and low-dose CPA in R/R DLBCL.

European journal of haematology（2023）

引用 0|浏览4

暂无评分

摘要

This immunotherapy combination was found to be active and safe in this clinically challenging patient population.

查看译文

关键词

check-point inhibitor, diffuse large B cell lymphoma, immunotherapy, maveropepimut-S, PD-L1

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要